alitretinoin

(redirected from Panretin)

alitretinoin

 [al″ĭ-tret´ĭ-noin″]
a topical antineoplastic used in the treatment of AIDS-related cutaneous Kaposi's sarcoma.

alitretinoin

Panretin

Pharmacologic class: Second-generation retinoid

Therapeutic class: Topical antineoplastic

Pregnancy risk category D

Action

Binds to and activates intracellular retinoid receptor subtypes, regulating expression of genes that control cellular differentiation and proliferation

Availability

Topical gel: 0.1%

Indications and dosages

Treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma

Adults: Apply to lesions b.i.d., gradually increasing to t.i.d. or q.i.d. according to individual lesion tolerance

Contraindications

• Hypersensitivity to retinoids or other drug components

Precautions

Use cautiously in:
• photosensitivity
• concomitant use of insecticides containing diethyltoluamide (DEET)
• elderly patients
• pregnant or breastfeeding patients
• children.

Administration

• Apply generous amount of gel to affected area. Let it dry for 3 to 5 minutes before covering with clothing.

Adverse reactions

CNS: paresthesia

Skin: rash, pruritus, exfoliative dermatitis, skin disorder at application site (such as abrasion, burning, blisters, excoriation, scab, cracking, crusting, drainage, eschar, fissure, oozing, peeling, redness, or swelling), edema

Other: pain, increased sensitivity to sunlight or sun lamps

Interactions

Drug-behaviors.DEET-containing insect repellents: increased adverse reactions to DEET

Patient monitoring

• Monitor patient for serious adverse effects, especially burns caused by exposure to sunlight or sun lamps.

Patient teaching

• Instruct patient to apply generous amount of gel to affected skin area and let dry for 3 to 5 minutes before covering area with clothing.
• Caution patient to avoid applying gel to mucous membranes or to normal skin surrounding lesions.

Inform patient that drug increases sensitivity to sunlight and that exposure to sunlight or sun lamps (even through window glass or on a cloudy day) may cause serious burn of treated areas. Caution him to avoid such exposure.
• Tell patient to avoid insect repellents containing DEET during therapy.
• Emphasize importance of keeping all medical appointments so prescriber can check progress and monitor for unwanted drug effects.
• Advise females of childbearing potential to avoid becoming pregnant while using this drug.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the behaviors mentioned above.

alitretinoin

/al·i·tret·i·noin/ (-tret´ĭ-noin″) a topical antineoplastic used in the treatment of AIDS-related cutaneous Kaposi's sarcoma.

alitretinoin

a second-generation retinoid.
indication It is used to treat the cutaneous lesions of Kaposi's sarcoma.
contraindications Known hypersensitivity and pregnancy prohibit this drug's use.
adverse effects Side effects include rash, stinging, warmth, redness, erythema, blistering, crusting, peeling, contact dermatitis, and pain at the site of application.
Mentioned in ?
References in periodicals archive ?
Before X-Ceptor, he was Vice President of Research at Ligand Pharmaceuticals and was project leader for multiple discovery programs, including the successful identification and development of Panretin and Targretin, retinoids approved by the FDA for the treatment of cancer.
Tokyo, Japan, Sept 8, 2006 - (JCN) - Eisai has announced that it signed a product acquisition agreement with California-based Ligand Pharmaceuticals for exclusive global rights for their four oncology-related products, ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.
The Receptos scientific management team has broad experience in the development and registration of therapeutics including rituximab, targretin, panretin, belatacept, abatacept, omalizumab, and others.
AVINZA, Targretin, ONTAK and Panretin were registered trademarks of Ligand Pharmaceuticals Incorporated as of September 30, 2006.
Prior to these positions, he was vice president of research at Ligand Pharmaceuticals, where he led the identification and development of Panretin and Targretin for the treatment of cancer, and trained at the Salk Institute.
Heyman was Vice President of Research at Ligand Pharmaceuticals and was project leader for multiple discovery programs including the successful identification and development of Panretin and Targretin, retinoids approved by the FDA for the treatment of cancer.
AVINZA, Targretin, ONTAK and Panretin are registered trademarks of Ligand Pharmaceuticals Incorporated.
Ligand's in-line drugs -- Ontak, Targretin capsules, and Targretin and Panretin gels -- all have the opportunity for sales growth through increased off-label use, in our opinion.
Three months ended Six months ended June 30, June 30, 2005 2004 2005 2004 (Restated) (Restated) AVINZA $27,461 $14,177 $49,458 $27,454 ONTAK 8,779 9,966 16,803 17,277 Targretin capsules 4,671 4,136 8,686 7,553 Targretin & Panretin gels 824 1,020 1,833 1,954 Total net product sales $41,735 $29,299 $76,780 $54,238
Full prescribing information for Targretin capsules, Panretin gel and ONTAK may be obtained from Ligand Professional Services by calling toll-free, 1-800-964-5836.
If approved, Panretin gel would provide the first topical therapy for